<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098891</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02634</org_study_id>
    <secondary_id>JHOC-J0438</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <secondary_id>CDR0000396776</secondary_id>
    <nct_id>NCT00098891</nct_id>
  </id_info>
  <brief_title>MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas</brief_title>
  <official_title>A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275 (NSC 706995, IND 61,198), in Combination With 13-Cis-Retinoic Acid in Metastatic Progressive Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of combining MS-275 with isotretinoin in treating&#xD;
      patients who have metastatic or advanced solid tumors or lymphomas. MS-275 may stop the&#xD;
      growth of cancer cells by blocking the enzymes necessary for their growth. Isotretinoin may&#xD;
      help cancer cells develop into normal cells. MS-275 may increase the effectiveness of&#xD;
      isotretinoin by making cancer cells more sensitive to the drug. MS-275 and isotretinoin may&#xD;
      also stop the growth of solid tumors or lymphomas by stopping blood flow to the cancer.&#xD;
      Combining MS-275 with isotretinoin may kill more cancer cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the dose-limiting toxicity and maximum tolerated dose of MS-275 when&#xD;
      administered with isotretinoin in patients with metastatic, progressive, refractory, or&#xD;
      unresectable solid tumors or lymphomas.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine, preliminarily, tumor response in patients treated with this regimen.&#xD;
&#xD;
      II. Determine the pharmacokinetic profile of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of MS-275.&#xD;
&#xD;
      Patients receive oral MS-275 once on days 1, 8, and 15 and oral isotretinoin twice daily on&#xD;
      days 1-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease&#xD;
      progression. Cohorts of 3-6 patients receive escalating doses of MS-275 until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at&#xD;
      the MTD.&#xD;
&#xD;
      Patients are followed monthly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities defined as an adverse event which is likely related to the study medication</measure>
    <time_frame>28 days</time_frame>
    <description>Graded using the CTCAE version 3.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of entinostat and isotretinoin in combination</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Up to day 21 of course 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Graded using the CTCAE version 3.0. Summarized by dose level.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Intraocular Lymphoma</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Primary Central Nervous System Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Small Intestine Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Stage IV Adult Burkitt Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage IV Adult Hodgkin Lymphoma</condition>
  <condition>Stage IV Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage IV Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage IV Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Stage IV Grade 1 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 2 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 3 Follicular Lymphoma</condition>
  <condition>Stage IV Mantle Cell Lymphoma</condition>
  <condition>Stage IV Marginal Zone Lymphoma</condition>
  <condition>Stage IV Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Stage IV Small Lymphocytic Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Waldenström Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (entinostat, isotretinoin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral MS-275 once on days 1, 8, and 15 and oral isotretinoin twice daily on days 1-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entinostat</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (entinostat, isotretinoin)</arm_group_label>
    <other_name>HDAC inhibitor SNDX-275</other_name>
    <other_name>SNDX-275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotretinoin</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (entinostat, isotretinoin)</arm_group_label>
    <other_name>13-CRA</other_name>
    <other_name>Amnesteem</other_name>
    <other_name>Cistane</other_name>
    <other_name>Claravis</other_name>
    <other_name>Sotret</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor or lymphoma&#xD;
&#xD;
               -  Metastatic, progressive, refractory, or unresectable disease&#xD;
&#xD;
               -  Not amenable to standard curative measures&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  No suspected Gilbert's syndrome&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No unstable cardiac arryhthmia&#xD;
&#xD;
          -  Able to take and retain oral medications&#xD;
&#xD;
          -  No malabsorption problems&#xD;
&#xD;
          -  No acute or chronic gastrointestinal condition&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double-method contraception 1 month before,&#xD;
             during, and 3 months after study treatment&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No weight loss &gt; 10% within the past 2 months&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biologic composition to MS-275 or isotretinoin&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No seizure disorder&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study participation&#xD;
&#xD;
          -  More than 4 weeks since prior anticancer vaccine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior anticancer immunotherapy&#xD;
&#xD;
          -  No concurrent anticancer vaccine therapy&#xD;
&#xD;
          -  No concurrent anticancer immunotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior anticancer chemotherapy (6 weeks for nitrosoureas,&#xD;
             mitomycin, or other agents known to cause prolonged marrow supression)&#xD;
&#xD;
          -  No concurrent anticancer chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior anticancer hormonal therapy except&#xD;
             gonadotropin-releasing hormone (GnRH) agonist therapy for non-castrated patients with&#xD;
             prostate cancer&#xD;
&#xD;
          -  Concurrent GnRH agonist therapy for non-castrated patients with prostate cancer&#xD;
             allowed&#xD;
&#xD;
          -  Concurrent luteinizing hormone-releasing hormone agonist therapy allowed provided&#xD;
             there is evidence of tumor progression&#xD;
&#xD;
          -  Concurrent adrenal steroid replacement therapy allowed&#xD;
&#xD;
          -  No concurrent ketoconazole as second-line hormonal treatment for prostate cancer&#xD;
&#xD;
          -  No concurrent corticosteroids except for treatment of refractory nausea or vomiting&#xD;
&#xD;
          -  No other concurrent anticancer hormonal therapy&#xD;
&#xD;
          -  More than 4 weeks since prior anticancer radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior palliative radiotherapy&#xD;
&#xD;
          -  No concurrent anticancer radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No prior MS-275&#xD;
&#xD;
          -  No prior oral isotretinoin&#xD;
&#xD;
               -  Isotretinoin for the treatment of acne allowed provided &gt; 3 years since prior&#xD;
                  administration&#xD;
&#xD;
          -  More than 4 weeks since other prior anticancer therapy&#xD;
&#xD;
          -  No concurrent tetracycline&#xD;
&#xD;
          -  No concurrent high-dose vitamin A&#xD;
&#xD;
          -  No concurrent valproic acid&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Pili</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-8936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>December 8, 2004</study_first_submitted>
  <study_first_submitted_qc>December 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2004</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Intraocular Lymphoma</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entinostat</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

